



SAS dsh 02/15/07 4239-66902-01 653123 E-183-2002/0-US-02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Klinman et al.

Application No. 10/682,130

Filed: October 7, 2003

Confirmation No. 1348

For: METHOD OF TREATING
INFLAMMATORY LUNG DISEASE
WITH SUPPRESSORS OF CPG
OLIGONUCLEOTIDES

Examiner: Patricia Ann Duffy

Art Unit: 1645

Attorney Reference No. 4239-66902-01

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s) _____

Date Mailed February 15, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and are several English-language and/or documents (one document enclosed). Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163).

Applicants will provide copies of such patents or applications upon request.

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-66902-01
	Application Number	10/682,130
	Filing Date	October 7, 2003
	First Named Inventor	Klinman
	Art Unit	1645
	Examiner Name	Patricia Ann Duffy

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		7,094,766	August 2006	Gilchrest et al.
		US2006/0074039	April 2006	Klinman et al.
		US2006/0132682	July 2004	Klinman et al.
		US2003/0087848	May 2003	Bratzler et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Iwakura et al., "The Development of Autoimmune Inflammatory Arthropathy in Mice Transgenic for the Human T Cell Leukemia Virus Type-1 <i>env-pX</i> Region is not Dependent on H-2 Haplotypes and Modified by the Expression Levels of Fas Antigen," <i>J. Immunology</i> 161:6592-6598, 1988

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-66902
Application Number	To be assigned
Filing Date	October 7, 2003
First Named Inventor	Klinman
Art Unit	To be assigned
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		6,214,806	4/10/2001	Krieg et al.

COPY

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Krieg et al., "Sequence Motifs in Adenoviral DNA Block Immune Activation by Stimulatory CpG Motifs," <i>Proc. Natl. Acad. Sci. USA</i> 95:12631-12636 (1998).
		Schwartz, CpG Motifs in Bacterial DNA Cause Inflammation in the Lower Respiratory Tract," <i>J. Clin. Invest.</i> 100:68-73 (1997).
		Schwartz, "Bacterial DNA or Oligonucleotides Containing Unmethylated CpG Motifs Can Minimize Lipopolysaccharide-Induced Inflammation in the Lower Respiratory Tract Through an IL-12-Dependent Pathway," <i>J. Immunol.</i> 163:224-231 (1999).

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-66902-01
Application Number	10/682,130
Filing Date	October 7, 2003
First Named Inventor	Klinman
Art Unit	1645
Examiner Name	Patricia Ann Duffy

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		4,469,863	4 Sep 1984	Ts'o <i>et al.</i>
		5,023,243	11 June 1991	Tullis
		5,663,153	2 Sep 1997	Hutcherson <i>et al.</i>
		US-2004-0132682-A1	8 July 2004	Klinman <i>et al.</i>
		US-2004-0248834-A1	9 Dec 2004	Klinman <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		EPC	EP 0 092 574	29 Apr 1992	Tullis
		WIPO/PCT	WO 83/01451	28 Apr 1983	Tullis
		WIPO/PCT	WO 95/26204	5 Sep 1995	Hutcherson <i>et al.</i>
		WIPO/PCT	WO 96/02555	1 Feb 1996	Krieg
		WIPO/PCT	WO 98/11211	19 Mar 1998	Agrawal
		WIPO/PCT	WO 98/18810	7 May 1998	Krieg <i>et al.</i>
		WIPO/PCT	WO 98/37919	3 Sep 1998	Schwartz <i>et al.</i>
		WIPO/PCT	WO 98/40100	17 Sep 1998	Davis <i>et al.</i>
		WIPO/PCT	WO 98/52581	26 Nov 1998	Davis <i>et al.</i>

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Attorney Docket Number		4239-66902-01	
				Application Number		10/682,130	
				Filing Date		October 7, 2003	
				First Named Inventor		Klinman	
				Art Unit		1645	
				Examiner Name		Patricia Ann Duffy	
		WIPO/PCT	WO 99/51259	14 Oct 1999	Krieg <i>et al.</i>		
		WIPO/PCT	WO 03/027313	3 April 2003	Klinman <i>et al.</i>		
		WIPO/PCT	WO 2004/012669	12 Feb 2004	Klinman <i>et al.</i>		
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS					
		BATTEGAY, "Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects," <i>J. Molec. Med.</i> 73(7): 333-346, 1995					
		BECK <i>et al.</i> , "Vascular development: cellular and molecular regulation," <i>FASEB J.</i> 11(5): 365, 1997					
		BJERSING <i>et al.</i> , "Anti-proliferative effects of phosphodiester oligodeoxynucleotides," <i>Immunobiology</i> , 209(8):637-45, 2004					
		BRAUN <i>et al.</i> , "On the Difficulties of Establishing a Consensus on the Definition of and Diagnostic Investigations for Reactive Arthritis," <i>J. Rheumatol.</i> 27:2185-2192, 2000					
		BRITIGAN <i>et al.</i> , "Lactoferrin Binds CpG-Containing Oligonucleotides and Inhibits Their Immunostimulatory Effects on Human B Cells," <i>J. Immunol.</i> 167:2921-2928, 2001					
		CHEN <i>et al.</i> , "Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs," <i>Gene Ther.</i> 8(13):1024-1032, 2001					
		DENG <i>et al.</i> , "Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis," <i>Nat. Med.</i> 5:702-705, 1999					
		DENG <i>et al.</i> , "Synovial cytokine mRNA expression during arthritis triggered by CpG motifs of bacterial DNA," <i>Arthritis Res.</i> 3(1):48-53, 2001					
		DENG <i>et al.</i> , "The Features of Arthritis Induced by CpG Motifs in Bacterial DNA," <i>Arthritis Rheum.</i> 43:356-364, 2000					
		GAUDRIC <i>et al.</i> "Quantification of Angiogenesis due to Basic Fibroblast Growth Factor in a Modified Rabbit Corneal Model," <i>Ophthalm. Res.</i> 24: 181, 1992					
		GURSEL <i>et al.</i> , "Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides," <i>J. Immunol.</i> 167: 3324, 2001					
		GURSEL <i>et al.</i> , "Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide," <i>J. Leuko.Biol.</i> 71:813-820, 2002					
		HAN <i>et al.</i> , "G-quadruplex DNA: a potential target for anti-cancer drug design," <i>Trends Pharmacol. Sci.</i> 21:136-142, 2000					
		HARTMANN <i>et al.</i> , "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells," <i>Proc. Natl. Acad. Sci. USA</i> 96:9305-9310, 1999					
EXAMINER SIGNATURE:				DATE CONSIDERED:			
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66902-01
		Application Number	10/682,130
		Filing Date	October 7, 2003
		First Named Inventor	Klinman
		Art Unit	1645
		Examiner Name	Patricia Ann Duffy
		HO <i>et al.</i> , "An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems," <i>J. Immunol.</i> 171:4920-4926, 2003	
		KENYON <i>et al.</i> , "A Model of Angiogenesis in the Mouse Cornea," <i>Invest Ophthalmol. Vis. Sci.</i> 37:1625-1632, 1996	
		KLINMAN <i>et al.</i> , "CpG Motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ ," <i>Proc. Natl. Acad. Sci. USA</i> 93:2879, 1996	
		KLINMAN <i>et al.</i> , "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," <i>J. Immunol.</i> 158:3635-3639, 1997	
		KLINMAN <i>et al.</i> , "Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety," <i>Springer Semin. Immunopathol.</i> 22:173-183, 2000	
		KRIEG <i>et al.</i> , "CpG motifs in bacterial DNA trigger direct B-cell activation," <i>Nature</i> 374:546-549, 1995	
		KRIEG, "Commentary: A possible cause of joint destruction in septic arthritis," <i>Arthritis Research</i> 1(1):3-4, 1999	
		KRIEG, "From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA," <i>Antisense Nucleic Acid Drug Dev</i> 11(3):181-188, 2001	
		KRIEG <i>et al.</i> , "Enhancing vaccines with immune stimulatory CpG DNA," <i>Curr Opin Mol Ther</i> 3(1):15-24, 2001	
		KRIEG, "From A to Z on CpG," <i>Trends Immunol.</i> 23(2):64-65, 2002	
		KRIEG, "CpG Motifs in bacterial DNA and their immune effects," <i>Annu Rev Immunol</i> 20:709-760, 2002	
		LENERT <i>et al.</i> , "CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation." <i>Antisense Nucleic Acid Drug Dev</i> 11(4):247-256, 2001	
		LIANG <i>et al.</i> , "Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides," <i>J. Clin. Invest.</i> 98:1119-1129, 1996	
		LICHTENBERG <i>et al.</i> , "The Rat Subcutaneous Air Sac Model: A Quantitative Assay of Antiangiogenesis in Induced Vessels," <i>Pharmacol Toxicol.</i> 84:34-40, 1999	
		MURCHIE <i>et al.</i> , "Tetraplex folding of telomere sequences and the inclusion of adenine bases," <i>EMBO J.</i> 13:993-1001, 1994	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66902-01
		Application Number	10/682,130
		Filing Date	October 7, 2003
		First Named Inventor	Klinman
		Art Unit	1645
		Examiner Name	Patricia Ann Duffy
		PISETSKY <i>et al.</i> , "Immunological Properties of Bacterial DNA," <i>NY Acad. Sci.</i> 772:152-163, 1995	
		PISETSKY <i>et al.</i> , "Inhibition of Murine Macrophage IL-12 Production by Natural and Synthetic DNA," <i>Clin. Immunol.</i> 96, 198-204, 2000	
		QUARCOO <i>et al.</i> , "Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity," <i>J Allergy Clin Immunol.</i> , 114(2):288-95, 2004	
		ROMAN <i>et al.</i> , "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants," <i>Nature Medicine</i> 3(8):849-854, 1997	
		STUNZ <i>et al.</i> , "Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells," <i>Eur J Immunol</i> 32(5):1212-1222, 2002	
		VERTHELYI <i>et al.</i> , "Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs," <i>J. Immunol.</i> 166:2372-2377, 2001	
		VIALAS <i>et al.</i> , "Oxidative Damage Generated by an Oxo-Metalloporphyrin onto the Human Telomeric Sequence," <i>Biochemistry</i> 39:9514-9522, 2000	
		WILTING <i>et al.</i> , "A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors," <i>Anat. Embryol.</i> 183: 259-271, 1991	
		YAMADA <i>et al.</i> , "Effect of Suppressive DNA on CpG-Induced Immune Activation," <i>J. Immunol.</i> 169:5590-5594, 2002	
		YAMAMOTO <i>et al.</i> , "Unique Pallindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity," <i>J. Immunol.</i> 148:4072-4076, 1992	
		YI <i>et al.</i> , "Rapid Immune Activation by CpG Motifs in Bacterial DNA," <i>J. Immun.</i> 157:5394-5402, 1996	
		ZEUNER <i>et al.</i> , "Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides," <i>Arthritis Rheum.</i> 46(8):2219-2224, 2002	
		ZHAO <i>et al.</i> , "Requirements for effective inhibition of immunostimulatory CpG motifs by neutralizing motifs," <i>Antisense Nucleic Acid Drug Dev.</i> 10(5):381-389, 2000	
		ZHENG <i>et al.</i> , "DNA containing CpG motifs induces angiogenesis," <i>PNAS</i> 99(13):8944-8949, 2002	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	